Woo Seok-min agreed to acquire 2.4% stake in Myungmoon Investment Development Co. Ltd. from MYUNGMOON Pharm co.,Ltd for KRW 2.1 billion.
June 24, 2021
Share
Woo Seok-min agreed to acquire 2.4% stake in Myungmoon Investment Development Co. Ltd. from MYUNGMOON Pharm co.,Ltd (KOSE:A017180) for KRW 2.1 billion on June 25, 2021. The deal is expected to be completed by June 25, 2021. Myungmoon Investment Development reported total assets of KRW 66.1 billion, total common equity of KRW 29.7 billion, total revenue of KRW 5.8 billion and net loss of KRW 0.9 billion for the year ending December 31, 2020.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
MYUNGMOON PHARM CO.,LTD 
